lower respiratory tract infections

Cefodizime is a third–generation cephalosporin for parenteral use that has become available for the first time in the Russia. This paper reviews the use of this antibiotic in clinical practice based on the current data on antimicrobial resistance in …

Objective. To review a literature published over the past 5 years and our own data on the etiology of lower respiratory tract infections (LRTI), antimicrobial resistance and its relationships between sepsis and choice of appropriate antibiotic therapy. Materials and Methods. National Nosocomial Infections Surveillance (NNIS) criteria were used to diagnose LRTI. A review of the articles regarding LRTI from the Russian and international English language journals published over 6 years was performed.

The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some …

Methods to improve patient compliance with treatment are rarely used by physicians in their practice. It may be in part because of the lack of adequate information on this issue. This paper reviews adherence of the patients with respiratory tract …

Azithromycin is one of the most commonly used macrolides in the treatment of respiratory tract infections. Azithromycin is a popular antimicrobial due to a number of its unique pharmacokinetic and pharmacodynamic properties. This review describes the …

According to the Guidelines of European Respiratory Society and European Society of Clinical Microbiology and Infectious Diseases.

Clinical guidelines that comply with the principles of evidence-based medicine are one of the most trustworthy sources …